PL2147594T3 - Wytwarzające przeciwciała ssaki inne niż człowiek - Google Patents

Wytwarzające przeciwciała ssaki inne niż człowiek

Info

Publication number
PL2147594T3
PL2147594T3 PL09075279T PL09075279T PL2147594T3 PL 2147594 T3 PL2147594 T3 PL 2147594T3 PL 09075279 T PL09075279 T PL 09075279T PL 09075279 T PL09075279 T PL 09075279T PL 2147594 T3 PL2147594 T3 PL 2147594T3
Authority
PL
Poland
Prior art keywords
human mammals
antibody producing
producing non
mammals
antibody
Prior art date
Application number
PL09075279T
Other languages
English (en)
Inventor
Erwin Houtzager
Rui Daniel Pinto
Ton Logtenberg
Mark Throsby
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41280336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2147594(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus Nv filed Critical Merus Nv
Publication of PL2147594T3 publication Critical patent/PL2147594T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09075279T 2008-06-27 2009-06-29 Wytwarzające przeciwciała ssaki inne niż człowiek PL2147594T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2008050430 2008-06-27
EP09075279.1A EP2147594B1 (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Publications (1)

Publication Number Publication Date
PL2147594T3 true PL2147594T3 (pl) 2014-04-30

Family

ID=41280336

Family Applications (3)

Application Number Title Priority Date Filing Date
PL09075279T PL2147594T3 (pl) 2008-06-27 2009-06-29 Wytwarzające przeciwciała ssaki inne niż człowiek
PL18183994.5T PL3456192T3 (pl) 2008-06-27 2009-06-29 Zastosowanie wytwarzających przeciwciała ssaków z gatunku myszy do wytwarzania przeciwciał o wysokim powinowactwie
PL18183980T PL3456190T3 (pl) 2008-06-27 2009-06-29 Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL18183994.5T PL3456192T3 (pl) 2008-06-27 2009-06-29 Zastosowanie wytwarzających przeciwciała ssaków z gatunku myszy do wytwarzania przeciwciał o wysokim powinowactwie
PL18183980T PL3456190T3 (pl) 2008-06-27 2009-06-29 Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy

Country Status (23)

Country Link
EP (7) EP2147594B1 (pl)
JP (6) JP5749161B2 (pl)
KR (5) KR101990228B1 (pl)
CN (3) CN112481300A (pl)
AU (1) AU2009263082C1 (pl)
CA (1) CA2729095C (pl)
CY (2) CY1114830T1 (pl)
DK (4) DK3456192T3 (pl)
ES (4) ES2853226T3 (pl)
FI (1) FI3456192T3 (pl)
HR (3) HRP20251477T1 (pl)
HU (1) HUE057994T2 (pl)
LT (2) LT3456190T (pl)
MX (1) MX2010014542A (pl)
NZ (1) NZ590118A (pl)
PL (3) PL2147594T3 (pl)
PT (4) PT3456190T (pl)
RS (3) RS62925B1 (pl)
RU (2) RU2559524C2 (pl)
SG (3) SG10201914027VA (pl)
SI (3) SI3456190T1 (pl)
WO (1) WO2009157771A2 (pl)
ZA (1) ZA201009312B (pl)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
DK3456192T3 (da) * 2008-06-27 2025-11-24 Merus Nv Anvendelse af antistof-producerende murine pattedyr for at generere antistoffer med høj affinitet
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
DK3028565T3 (da) 2009-07-08 2017-11-13 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
MX2012009168A (es) * 2010-02-08 2012-08-31 Regeneron Pharma Raton de cadena ligera comun.
KR20210010942A (ko) 2010-03-31 2021-01-28 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
WO2012018610A2 (en) 2010-07-26 2012-02-09 Trianni, Inc. Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2947151A1 (en) * 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
HRP20241480T1 (hr) 2011-08-05 2025-01-03 Regeneron Pharmaceuticals, Inc. Humanizirani miševi univerzalnog lakog lanca
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201403223PA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
NZ793447A (en) * 2012-02-01 2024-05-31 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
RU2683514C2 (ru) * 2012-03-06 2019-03-28 Регенерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
ES2849349T3 (es) 2012-03-16 2021-08-17 Regeneron Pharma Anticuerpos de cadena ligera modificados mediante ingeniería con histidina y roedores modificados genéticamente para la generación de los mismos
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
RU2014141536A (ru) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN107383197B (zh) 2012-04-20 2021-12-10 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
WO2013184761A1 (en) * 2012-06-05 2013-12-12 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
SG10201605703TA (en) 2012-07-06 2016-09-29 Genmab Bv Dimeric protein with triple mutations
CN103571872B (zh) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
ES2942413T3 (es) * 2013-03-13 2023-06-01 Regeneron Pharma Ratones que expresan un repertorio limitado de cadenas ligeras de inmunoglobulina
US10201614B2 (en) 2013-03-15 2019-02-12 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
WO2015057758A1 (en) * 2013-10-15 2015-04-23 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
KR20240042540A (ko) 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
GB2526867A (en) * 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
KR102609034B1 (ko) 2014-09-17 2023-12-01 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
HK1250038A1 (zh) 2015-03-19 2018-11-23 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
LT3115376T (lt) 2015-07-10 2018-11-12 Merus N.V. Antikūnai, kurie jungiasi su žmogaus cd3
RU2018110364A (ru) 2015-08-24 2019-09-26 Трианни, Инк. Усовершенствованное продуцирование иммуноглобулинов
RS61800B1 (sr) 2015-10-23 2021-06-30 Merus Nv Vezujući molekuli koji inhibiraju rast kancera
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
US10980221B2 (en) * 2016-06-03 2021-04-20 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
US11827876B2 (en) 2016-08-12 2023-11-28 Oxitec Ltd. Self-limiting, sex-specific gene and methods of using
WO2018056821A1 (en) 2016-09-23 2018-03-29 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CN110637083A (zh) * 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
IL269655B2 (en) 2017-03-31 2023-09-01 Merus Nv An erbb-2-targeted agent and a bispecific antibody with antigen-binding sites that bind epitopes on the extracellular part of erbb-2 and erbb-3, for the treatment of individuals with erbb-2, erbb-2/erbb-3 positive cancer tumors
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
KR102744809B1 (ko) 2017-05-17 2024-12-23 메뤼스 엔.페. 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합
CN119119284A (zh) 2017-07-06 2024-12-13 美勒斯公司 调节由细胞表达的生物活性的结合分子
EA202090004A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Биспецифические антитела против pd-1 и против tim-3
IL271833B2 (en) 2017-07-06 2024-09-01 Merus Nv Antibodies that modulate a biological activity expressed by a cell
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
EP3717008A1 (en) 2017-12-01 2020-10-07 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
RS63772B1 (sr) * 2017-12-05 2022-12-30 Regeneron Pharma Miševi koji imaju modifikovani lambda laki lanac imunoglobulina i njihove upotrebe
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
CA3093995A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
AR117409A1 (es) 2018-03-29 2021-08-04 Oxitec Ltd Noctuidas autolimitantes
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
WO2019236670A1 (en) * 2018-06-08 2019-12-12 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain i
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP2022521036A (ja) 2018-12-20 2022-04-05 メルス ナムローゼ フェンノートシャップ ＣＬＥＣ１２ＡｘＣＤ３二重特異性抗体及び疾患の治療方法
US12467062B2 (en) 2018-12-21 2025-11-11 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
WO2020141974A1 (en) 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
AR117741A1 (es) * 2018-12-31 2021-08-25 Merus Nv Dominios de unión mixtos
PH12021551783A1 (en) 2019-01-22 2022-05-30 Bristol Myers Squibb Co Antibodies against il-7r alpha subunit and uses thereof
PH12021551959A1 (en) 2019-02-14 2022-07-18 Merus Nv Combinations of binding moieties that bind egfr, her2 and her3.
JP7375027B2 (ja) 2019-02-14 2023-11-07 メルス ナムローゼ フェンノートシャップ ２つ以上の抗体を含む組成物の製造
JP7670627B2 (ja) 2019-02-18 2025-04-30 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
TW202546002A (zh) 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
TW202509079A (zh) * 2019-04-04 2025-03-01 日商小野藥品工業股份有限公司 雙特異性抗體
CN114702587A (zh) 2019-05-09 2022-07-05 美勒斯公司 用于使蛋白质多聚化的变体结构域及其分离
JP7744248B2 (ja) * 2019-07-01 2025-09-25 トリアニ・インコーポレイテッド トランスジェニック哺乳動物およびその使用法
TWI889320B (zh) 2019-07-05 2025-07-01 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
WO2021020416A1 (ja) * 2019-07-30 2021-02-04 小野薬品工業株式会社 二重特異性抗体
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
WO2021034194A2 (en) 2019-08-19 2021-02-25 Merus N.V. Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor.
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
WO2021133167A1 (en) 2019-12-24 2021-07-01 Merus N.V. Tgf-beta-rii binding proteins
IL294368A (en) 2020-01-29 2022-08-01 Merus Nv Means and method for modulating mixed effects in immune cells
CN115698067A (zh) 2020-04-24 2023-02-03 美勒斯公司 使用结合lgr5及egfr的抗体的癌症治疗
CA3182925A1 (en) 2020-06-02 2021-12-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
JP7714992B2 (ja) * 2020-10-02 2025-07-30 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
MX2023006983A (es) 2020-12-15 2023-06-26 Merus Nv Tratamiento de canceres con un anticuerpo que se une al receptor 5 acoplado a proteina g (lgr5) y al receptor del factor de crecimiento epidermico (egfr).
CN116710486A (zh) 2020-12-16 2023-09-05 美勒斯公司 用于治疗癌症的多特异性抗体
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
MX2023007309A (es) 2020-12-18 2023-08-14 Merus Nv Composicion de anticuerpos.
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途
CN120504741A (zh) 2021-10-06 2025-08-19 美勒斯公司 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
WO2023146394A1 (en) 2022-01-25 2023-08-03 Merus N.V. Combination therapy for the treatment of cancer
JP2025509312A (ja) 2022-03-07 2025-04-11 メルス ナムローゼ フェンノートシャップ ＥＧＦＲ及びｃＭＥＴに結合する抗体を含む併用療法
TW202346353A (zh) 2022-03-07 2023-12-01 荷蘭商美勒斯公司 利用結合EGFR及cMET之抗體的治療
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
AU2023408531A1 (en) 2022-12-23 2025-07-17 Merus B.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
JP2026500788A (ja) 2022-12-28 2026-01-08 メルス ナムローゼ フェンノートシャップ Ｅｇｆｒに結合する抗体及び細胞傷害性薬の組み合わせを用いたがんの治療
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) * 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
AU3328493A (en) * 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
CN1161614C (zh) * 1998-03-30 2004-08-11 研究发展基金会 用促肾上腺皮质素释放因子受体-1缺陷型小鼠鉴定促效剂和拮抗剂的方法
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100583331B1 (ko) * 2001-05-11 2006-05-26 기린 비루 가부시키가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물
PT1523496E (pt) * 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
EP1439234A1 (en) * 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
AU2006242854A1 (en) * 2005-04-29 2006-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
PT2769992T (pt) 2006-10-02 2021-03-11 Regeneron Pharma Anticorpos humanos com elevada afinidade para o receptor de il-4 humana
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
DK3456192T3 (da) * 2008-06-27 2025-11-24 Merus Nv Anvendelse af antistof-producerende murine pattedyr for at generere antistoffer med høj affinitet
MX2012009168A (es) * 2010-02-08 2012-08-31 Regeneron Pharma Raton de cadena ligera comun.
IT202300006069A1 (it) 2023-03-29 2024-09-29 Comecer Spa Contenitore modulare per trasportare radiofarmaci o farmaci termolabili

Also Published As

Publication number Publication date
EP3456190B1 (en) 2021-11-24
HRP20140139T1 (hr) 2014-03-14
RU2731084C2 (ru) 2020-08-28
PT2556747T (pt) 2021-02-15
CA2729095C (en) 2018-12-04
JP2024063038A (ja) 2024-05-10
KR102306491B1 (ko) 2021-09-29
CN105191863A (zh) 2015-12-30
EP2556747A3 (en) 2016-08-03
ES3053014T3 (en) 2026-01-16
SG10201914027VA (en) 2020-03-30
WO2009157771A3 (en) 2010-02-18
SG10201914019YA (en) 2020-03-30
EP2147594B1 (en) 2013-11-13
HK1154463A1 (zh) 2012-04-27
JP5749161B2 (ja) 2015-07-15
PL3456192T3 (pl) 2026-02-23
ES2853226T3 (es) 2021-09-15
RU2020127564A (ru) 2022-02-21
DK2556747T3 (da) 2021-02-15
ES2906344T3 (es) 2022-04-18
PT2147594E (pt) 2014-02-17
RU2559524C2 (ru) 2015-08-10
SI3456190T1 (sl) 2022-06-30
EP3456191A1 (en) 2019-03-20
KR102112655B1 (ko) 2020-05-19
JP2022188085A (ja) 2022-12-20
RU2011102962A (ru) 2012-08-10
SI3456192T1 (sl) 2026-01-30
CY1114830T1 (el) 2016-12-14
PT3456192T (pt) 2025-11-19
CN112481300A (zh) 2021-03-12
RU2015119670A (ru) 2015-12-10
JP2017121256A (ja) 2017-07-13
CN102123582B (zh) 2015-09-30
AU2009263082B9 (en) 2014-07-17
CN102123582A (zh) 2011-07-13
SI2147594T1 (sl) 2014-02-28
ZA201009312B (en) 2011-08-31
KR102261586B1 (ko) 2021-06-08
LT3456192T (lt) 2025-12-10
RS62925B1 (sr) 2022-03-31
HRP20220205T1 (hr) 2022-05-27
RU2020127564A3 (pl) 2022-02-21
AU2009263082C1 (en) 2018-11-01
EP4650441A3 (en) 2026-02-18
FI3456192T3 (fi) 2025-12-03
JP2015156871A (ja) 2015-09-03
KR20140127914A (ko) 2014-11-04
NZ590118A (en) 2012-10-26
MX2010014542A (es) 2011-04-05
KR20190025068A (ko) 2019-03-08
AU2009263082A1 (en) 2009-12-30
JP2011525808A (ja) 2011-09-29
KR20110029156A (ko) 2011-03-22
KR101990228B1 (ko) 2019-06-17
CY1125119T1 (el) 2023-06-09
EP2556747A2 (en) 2013-02-13
EP3456193A1 (en) 2019-03-20
JP6824807B2 (ja) 2021-02-03
DK2147594T3 (da) 2014-02-10
RU2015119670A3 (pl) 2019-01-22
PL3456190T3 (pl) 2022-06-06
DK3456192T3 (da) 2025-11-24
EP3456192A1 (en) 2019-03-20
EP3456190A1 (en) 2019-03-20
WO2009157771A2 (en) 2009-12-30
EP3456192B1 (en) 2025-09-03
JP2020191882A (ja) 2020-12-03
KR20170066688A (ko) 2017-06-14
RS67450B1 (sr) 2025-12-31
ES2445193T3 (es) 2014-02-28
DK3456190T3 (da) 2022-02-14
EP4650441A2 (en) 2025-11-19
AU2009263082B2 (en) 2014-03-20
SG10201408500RA (en) 2015-01-29
CA2729095A1 (en) 2009-12-30
PT3456190T (pt) 2022-02-15
EP2556747B1 (en) 2020-12-02
HUE057994T2 (hu) 2022-06-28
LT3456190T (lt) 2022-03-10
KR20200057093A (ko) 2020-05-25
JP7242611B2 (ja) 2023-03-20
RS53146B (sr) 2014-06-30
EP2147594A1 (en) 2010-01-27
CN105191863B (zh) 2020-12-22
JP7439201B2 (ja) 2024-02-27
HRP20251477T1 (hr) 2026-01-16

Similar Documents

Publication Publication Date Title
SG10201914019YA (en) Antibody producing non-human mammals
ZA201102119B (en) Improved antibody libraies
IL212701A0 (en) Improved anti-cd19 antibodies
IL212633A0 (en) c-MET ANTIBODIES
PL2262831T3 (pl) Przeciwciała przeciwko properdynie
SG10201601279SA (en) Monoclonal Antibody STRO-4
GB0821100D0 (en) Antibodies
SG10201403703XA (en) Methods of producing humanized non-human mammals
IL207581A0 (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB2473934A8 (en) Antibody
GB0911770D0 (en) Antibody
EP2264071A4 (en) ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION
FI20085308A0 (fi) Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä
GB0820307D0 (en) Antibody production
GB0815963D0 (en) Antibody production
PL384301A1 (pl) Urządzenie do produkcji biopaliwa
GB0819113D0 (en) An antibody
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody
GB0804687D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
GB0823562D0 (en) Antibodies